Merck Stock Rises Despite Revenue Forecast Miss, Highlighting Pharma Sector Volatility
Merck & Co (NYSE:MRK) shares gained 2.2% in after-hours trading, closing at $115.84 after a volatile session that saw swings between $109.02 and $118.35. The movement comes despite the company's 2026 revenue projection of $65.5-$67.0 billion falling short of Wall Street's $67.6 billion expectation.
Investors appear focused on Merck's strategic positioning rather than near-term numbers, particularly around its oncology portfolio. Keytruda continues to demonstrate strong growth, while patent expirations loom for older medications - a classic pharmaceutical industry tension between pipeline potential and revenue pressures.
The market is closely monitoring demand trends for Merck's flagship drugs Keytruda and Gardasil, along with upcoming regulatory decisions including the FDA's Winrevair label update. These factors will likely drive the stock's performance through 2024.
